HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors.

Abstract
Neutrophil elastase and cathepsin G are abundant intracellular neutrophil proteinases that have an important role in destroying ingested particles. However, when neutrophils degranulate, these proteinases are released and can cause irreparable damage by degrading host connective tissue proteins. Despite abundant endogenous inhibitors, these proteinases are protected from inhibition because of their ability to bind to anionic surfaces. Plasminogen activator inhibitor type-1 (PAI-1), which is not an inhibitor of these proteinases, possesses properties that could make it an effective inhibitor of neutrophil proteinases if its specificity could be redirected. PAI-1 efficiently inhibits surface-sequestered proteinases, and it efficiently mediates rapid cellular clearance of PAI-1-proteinase complexes. Therefore, we examined whether PAI-1 could be engineered to inhibit and clear neutrophil elastase and cathepsin G. By introducing specific mutations in the reactive center loop of wild-type PAI-1, we generated PAI-1 mutants that are effective inhibitors of both proteinases. Kinetic analysis shows that the inhibition of neutrophil proteinases by these PAI-1 mutants is not affected by the sequestration of neutrophil elastase and cathepsin G onto surfaces. In addition, complexes of these proteinases and PAI-1 mutants are endocytosed and degraded by lung epithelial cells more efficiently than either the neutrophil proteinases alone or in complex with their physiological inhibitors, alpha1-proteinase inhibitor and alpha1-antichymotrypsin. Finally, the PAI-1 mutants were more effective in reducing the neutrophil elastase and cathepsin G activities in an in vivo model of lung inflammation than were their physiological inhibitors.
AuthorsSteingrimur Stefansson, Manuel Yepes, Natalia Gorlatova, Duane E Day, Elisabeth G Moore, Adriana Zabaleta, Grainne A McMahon, Daniel A Lawrence
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 279 Issue 29 Pg. 29981-7 (Jul 16 2004) ISSN: 0021-9258 [Print] United States
PMID15131125 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anions
  • Enzyme Inhibitors
  • Plasminogen Activator Inhibitor 1
  • alpha 1-Antichymotrypsin
  • alpha 1-Antitrypsin
  • Cathepsins
  • Serine Endopeptidases
  • CTSG protein, human
  • Cathepsin G
  • Ctsg protein, mouse
  • Leukocyte Elastase
Topics
  • Animals
  • Anions
  • Cathepsin G
  • Cathepsins (antagonists & inhibitors, metabolism)
  • Dose-Response Relationship, Drug
  • Endocytosis
  • Endothelial Cells (metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Inflammation
  • Kinetics
  • Leukocyte Elastase (antagonists & inhibitors, metabolism)
  • Lung (cytology, metabolism, pathology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mutation
  • Neutrophils (metabolism)
  • Pancreas (enzymology)
  • Plasminogen Activator Inhibitor 1 (genetics)
  • Serine Endopeptidases
  • Time Factors
  • alpha 1-Antichymotrypsin (metabolism)
  • alpha 1-Antitrypsin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: